ReviewNutrients2021
Albumin Substitution in Decompensated Liver Cirrhosis: Don't Forget Zinc.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Zinc supplementation in liver cirrhosis: meta-analysis of its effect on biochemical and clinical outcomes.BMC nutrition · 2026Pooled it
- Albumin as a predictor of periprosthetic joint infection in patients undergoing total hip arthroplasty and total knee arthroplasty: a retrospective study.Journal of orthopaedic surgery and research · 2026Article
- Human serum albumin profiling by top-down analysis enables multi-class liver fibrosis staging: a cross-platform validation study.Scientific reports · 2026Article
- Use of Human Serum Albumin in Critically Ill Patients: A Narrative Review.Journal of clinical medicine · 2026Review
- Understanding acute kidney injury in cirrhosis: Current perspective.World journal of hepatology · 2025Review
- Association of alkaline phosphatase to albumin ratio with all-cause mortality in critically ill patients with cirrhosis: a retrospective study.BMC gastroenterology · 2025Article
- The role of the advanced lung cancer inflammation index (ALI) in the risk of liver fibrosis and mortality among US adult MAFLD patients: a cross-sectional study of NHANES 1999-2018.BMC gastroenterology · 2025Article
- Therapeutic potential of zincFrontiers in pharmacology · 2025Article
- Acute and sub-acute toxicity study of aqueous and methanol root extract ofToxicology reports · 2024Article
- Transferrin levels are associated with malnutrition markers in hemodialysis patients in KwaZulu-Natal, South Africa.Renal failure · 2024Article
- Serum trace element alterations in Indian patients with metabolic dysfunction-associated steatotic liver disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Article
- Evaluation of the nutritional status of patients with liver cirrhosis.World journal of hepatology · 2023Article
- Zinc: an undervalued microelement in research and treatment.Postepy dermatologii i alergologii · 2023Review
- Zinc's Association with the CmPn/CmP Signaling Network in Breast Cancer Tumorigenesis.Biomolecules · 2022Review
- Therapeutic effect of autologous bone marrow cells injected into the liver under the guidance of B‑ultrasound in the treatment of HBV‑related decompensated liver cirrhosis.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decompensated liver cirrhosis has a dismal prognosis, with patients surviving on average for 2-4 years after the first diagnosis of ascites. Albumin is an important tool in the therapy of cirrhotic ascites. By virtue of its oncotic properties, it reduces the risk of cardiovascular dysfunction after paracentesis. Treatment with albumin also counteracts the development of hepatorenal syndrome and spontaneous bacterial peritonitis. More recently, the positive impact of long-term albumin supplementation in liver disease, based on its pleiotropic non-oncotic activities, has been recognized. These include transport of endo- and exogenous substances, anti-inflammatory, antioxidant and immunomodulatory activities, and stabilizing effects on the endothelium. Besides the growing recognition that effective albumin therapy requires adjustment of the plasma level to normal physiological values, the search for substances with adjuvant activities is becoming increasingly important. More than 75% of patients with decompensated liver cirrhosis do not only present with hypoalbuminemia but also with zinc deficiency. There is a close relationship between albumin and the essential trace element zinc. First and foremost, albumin is the main carrier of zinc in plasma, and is hence critical for systemic distribution of zinc. In this review, we discuss important functions of albumin in the context of metabolic, immunological, oxidative, transport, and distribution processes, alongside crucial functions and effects of zinc and their mutual dependencies. In particular, we focus on the major role of chronic inflammatory processes in pathogenesis and progression of liver cirrhosis and how albumin therapy and zinc supplementation may affect these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.